Human Cell and Tissue Products Are Creating a Distinct Regulatory Affairs Hiring Niche

Introduction

Mention cell and tissue regulatory work to most people in the field and they picture CAR-T therapies, gene editing, and the full biologics license application pathway that products like these require. That picture is accurate for one category of cell and tissue products, but it leaves out a much larger and quietly growing corner of the field: human cells, tissues, and cellular and tissue-based products, known in the United States by the acronym HCT/Ps, which run under a different regulatory framework entirely. Bone and tendon allografts, skin substitutes, corneas, heart valves, and amniotic membrane products all fall into this category, and the regulatory and compliance professionals who work on them have a genuinely distinct job from their counterparts in cell and gene therapy. This article looks at what separates HCT/P regulatory work from the rest of the field, why hiring demand in this niche has been building, and what it takes to move into it.

What Counts as an HCT/P

An HCT/P, under FDA's framework in 21 CFR Part 1271, is broadly any article containing or consisting of human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient. That definition covers a wide and fairly ordinary range of products: musculoskeletal allografts used in orthopedic surgery, skin allografts and acellular dermal matrices used in wound care and reconstructive procedures, corneal tissue for transplant, cardiovascular tissue such as heart valves, and reproductive tissue including sperm, oocytes, and embryos. Many of these products have been used in surgery for decades, long before the current regulatory framework existed, and the framework itself was built specifically to address the communicable disease risk that comes with using human-derived material rather than to evaluate the kind of clinical efficacy question a drug or biologic review normally asks.

The Line That Defines the Work

The single most consequential regulatory question for any HCT/P is whether it qualifies for the streamlined Section 361 pathway or whether it falls instead under Section 351 of the Public Health Service Act, which treats it as a biologic requiring an investigational new drug application and, eventually, a full biologics license application. A product qualifies for the 361 pathway only if it meets four specific criteria: it is minimally manipulated, it is intended for homologous use only, meaning it performs the same basic function in the recipient that it performed in the donor, it is not combined with another article except for water, crystalloids, or a sterilizing, preserving, or storage agent, and it either has no systemic effect and does not depend on the metabolic activity of living cells, or if it does have such a dependency, it is used in specific narrow circumstances such as autologous use or use between close relatives.

Products that meet all four criteria can be marketed through establishment registration and listing with FDA, without the premarket review that a drug or biologic requires. Products that fail even one of the four criteria are regulated as 351 products and need the same kind of clinical development and approval pathway as a cell or gene therapy. This distinction is not a minor technicality. It determines whether a company can bring a product to market in a matter of months through registration, or whether it faces years of clinical development and a formal approval process, and getting the classification wrong, in either direction, creates real regulatory risk.

Donor Eligibility and Good Tissue Practice

Even for products on the lighter-touch 361 pathway, HCT/P regulation is far from hands-off. Establishments that recover, process, store, or distribute HCT/Ps have to comply with donor eligibility requirements, which include screening and testing donors for relevant communicable disease agents, and with Good Tissue Practice requirements that cover facility controls, process validation, labeling, and recordkeeping. Establishments register with FDA and are subject to inspection, and they are required to report adverse reactions associated with their products. Many tissue banks and processors also pursue voluntary accreditation through the American Association of Tissue Banks, whose standards overlap with but go beyond FDA's baseline requirements and are widely treated as the practical benchmark in the industry.

Why Hiring Demand Is Growing Here

Several forces have been pushing hiring demand in this niche upward. The underlying clinical use of allograft and tissue-based products has expanded steadily, particularly in orthopedics, sports medicine, and wound care, where tissue-based products are now a routine part of many procedures. At the same time, FDA has sharpened its enforcement focus on products marketed as minimally manipulated 361 tissue products that the agency views as actually requiring the full 351 pathway, particularly certain amniotic and placental tissue products and some adipose-derived products marketed with regenerative medicine claims that go beyond homologous use. That enforcement attention has pushed companies in this space to invest more seriously in regulatory and compliance expertise rather than treating classification as a settled question they can assume their way past.

The combination of routine clinical growth and heightened regulatory scrutiny has created a specific kind of hiring gap: companies need people who genuinely understand the 361/351 distinction, donor eligibility and Good Tissue Practice requirements, and the practical realities of tissue recovery and processing, and that combination of knowledge is less common than general biologics or device regulatory experience.

What the Job Actually Looks Like

Day to day, a regulatory affairs or compliance professional working on HCT/Ps spends real time on classification analysis, building and documenting the rationale for why a given product meets the minimal manipulation and homologous use criteria, since that analysis is what a company would need to defend if FDA questioned it. They work closely with tissue recovery and processing operations to make sure donor eligibility determinations and Good Tissue Practice controls are actually being followed in practice, not just on paper, and they manage establishment registration and listing, labeling compliance, and adverse reaction reporting. For companies working with products closer to the 361/351 boundary, such as certain processed or minimally manipulated amniotic tissue products, the role also involves staying current on FDA's enforcement priorities and guidance, since the agency's thinking on where exactly that line falls has continued to evolve.

Skills That Matter

• Working knowledge of 21 CFR Part 1271 and the specific four-part test that separates 361 products from 351 products
• Familiarity with donor eligibility screening and testing requirements and Good Tissue Practice controls
• Comfort with tissue recovery and processing operations, not just regulatory paperwork, since classification decisions depend on understanding what actually happens to the tissue
• Awareness of American Association of Tissue Banks accreditation standards and how they relate to FDA's baseline requirements
• Judgment about when a product's marketing claims or processing steps push it from minimal manipulation toward something that would require a 351 pathway

Where This Work Is Concentrated

Hiring in this niche is concentrated at tissue banks and processors, orthopedic and wound care device companies that incorporate allograft or tissue-based components into their product lines, ophthalmic tissue banks handling corneal transplant material, and a smaller group of regulatory consultancies that specifically support tissue establishments through registration, accreditation, and FDA inspection readiness. It is a smaller hiring pool than cell and gene therapy or traditional medical device regulatory work, which is part of why genuine HCT/P experience tends to be valued highly when a company does need to fill a role in this space.

How People Build a Career in This Niche

Few regulatory professionals set out to specialize in HCT/Ps. Most arrive here from quality or regulatory roles at tissue banks or orthopedic device companies, where they gradually take on more responsibility for classification decisions and establishment compliance, or from broader biologics regulatory backgrounds where they develop an interest in the specific mechanics of tissue-based products. Because the field is relatively small and the regulatory framework is genuinely distinct from both standard device and standard biologics work, people who build real depth here, especially in classification judgment and donor eligibility compliance, tend to find that expertise travels well across tissue banks, processors, and the consultancies that support them.

Conclusion

HCT/P regulatory work sits in a part of the field that gets less attention than cell and gene therapy but carries its own real technical depth and its own growing hiring demand. For regulatory professionals willing to build genuine expertise in tissue recovery operations, donor eligibility, and the classification judgment that determines which pathway a product follows, it is a durable specialization in a corner of the industry that is not going away, and one where the pool of people with real hands-on experience remains comparatively small.